Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2015

Autores

Costa Monteiro, IDC (Autor) Outra; Madureira, P (Autor) Outra; de Vasconscelos, A (Autor) Outra; Daniel Pozza (Autor) FMUP; de Mello, RA (Autor) Outra

Revista

Título: Pharmacogenomics

Vol. 16

Páginas: 257-271

ISSN: 1462-2416

Editora: ASHLEY PUBLICATIONS LTD

Indexação

ISI Web of Knowledge - 22 Citações

Scopus - 20 Citações

Outras Informações

ID Authenticus: P-00A-7CM

DOI: 10.2217/pgs.14.133

Abstract (EN): HER2-targeted therapies have radically changed the prognosis of HER2-positive breast cancer over the last few years. However, resistance to these therapies has been a constant, leading to treatment-failure and new tumor progression. Recently, the kinase-impaired HER3 emerged as a pivotal player in oncogenic signaling, with an important role in both non-treated progression and treatment response. HER2/HER3 dimerization is required for full signaling potential and constitutes the key oncogenic unit. Also, when inhibiting PI3K/AKT pathway (as with anti-HER2 drugs) feedback mechanisms lead to a rebound in HER3 activity, which is one of the main roads to resistance. As current strategies to treat HER2-positive breast cancer are unable to inhibit this feedback response, two great promises emerged: the combination of targeted-therapies and drugs targeting HER3. In this article HER2 and HER3-targeted drugs and possible combinations between them, as well as the biomarkers to predict and monitor these drugs effect, are reviewed.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 15